先天性垂体功能减退症及相关疾病的分子基础
本文综述了先天性垂体功能减退症(CH)的分子遗传学基础,涉及下丘脑-垂体发育相关的基因与信号通路。CH可表现为新生儿期或儿童期激素缺乏,并可能伴颅面中线结构异常、视力损害或前脑中线缺陷。近5年二代测序发现的新基因变异使已知致病基因列表迅速增加,但多数患者仍无法明确分子病因,给临床管理带来挑战。
要点
- CH由下丘脑-垂体发育相关基因突变所致,常伴颅面中线及前脑结构异常。
- 二代测序扩展了CH候选基因谱,但多数患者仍无明确分子诊断。
- 基于患者表型选择基因检测有助于提高遗传诊断率并指导临床管理。
核心结论
- CH及相关疾病的分子基础涉及下丘脑-垂体发育通路的多个基因突变,但多数患者分子病因未明。
研究设计与样本
- 本文为小型综述,讨论下丘脑-垂体发育相关基因与通路及其突变如何导致CH。
主要发现
- CH可表现为6种腺垂体激素中一种或多种缺乏,由5种特化细胞类型分泌。
- CH可在新生儿期或儿童期起病,可伴唇裂/腭裂、视神经发育不良、小眼/无眼或前脑中线缺陷。
- 已知致病基因常被筛查,近5年二代测序发现的新基因变异使列表迅速增加。
- 多数患者未发现明确分子基础,常使管理具有挑战性。
临床怎么用
- 临床应根据患者表型选择基因检测以辅助遗传诊断。
- 遗传诊断可能影响CH患者的临床管理。
局限性
- 多数患者仍无明确分子诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Congenital hypopituitarism (CH) is characterized by the presence of deficiencies in one or more of the 6 anterior pituitary (AP) hormones secreted from the 5 different specialized cell types of the AP. During human embryogenesis, hypothalamo-pituitary (HP) development is controlled by a complex spatio-temporal genetic cascade of transcription factors and signaling molecules within the hypothalamus and Rathke's pouch, the primordium of the AP. EVIDENCE ACQUISITION: This mini-review discusses the genes and pathways involved in HP development and how mutations of these give rise to CH. This may present in the neonatal period or later on in childhood and may be associated with craniofacial midline structural abnormalities such as cleft lip/palate, visual impairment due to eye abnormalities such as optic nerve hypoplasia (ONH) and microphthalmia or anophthalmia, or midline forebrain neuroradiological defects including agenesis of the septum pellucidum or corpus callosum or the more severe holoprosencephaly. EVIDENCE SYNTHESIS: Mutations give rise to an array of highly variable disorders ranging in severity. There are many known causative genes in HP developmental pathways that are routinely screened in CH patients; however, over the last 5 years this list has rapidly increased due to the identification of variants in new genes and pathways of interest by next-generation sequencing. CONCLUSION: The majority of patients with these disorders do not have an identified molecular basis, often making management challenging. This mini-review aims to guide clinicians in making a genetic diagnosis based on patient phenotype, which in turn may impact on clinical management.
引用
- Gregory LC, Dattani MT. The Molecular Basis of Congenital Hypopituitarism and Related Disorders. J Clin Endocrinol Metab. 2020. PMID: 31702014. doi:10.1210/clinem/dgz184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。